Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.
Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.
Matteucci
D
D
Department of Biomedicine, University of Pisa, Italy.
Pistello
M
M
Mazzetti
P
P
Giannecchini
S
S
Del Mauro
D
D
Lonetti
I
I
Zaccaro
L
L
Pollera
C
C
Specter
S
S
Bendinelli
M
M
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D002415:Cats; D002474:Cell-Free System; D004195:Disease Models, Animal; D005260:Female; D007117:Immunization, Secondary; D016089:Immunodeficiency Virus, Feline / Q000276:immunology*; D007156:Immunologic Memory; D012367:RNA, Viral / Q000032:analysis; D013997:Time Factors; D014611:Vaccination
D016915:AIDS Vaccines; D000956:Antigens, Viral; D012367:RNA, Viral